SplitJun 2, 2026, 08:51 AM
IceCure Medical Announces 1-for-30 Reverse Share Split for Nasdaq Compliance
AI Summary
IceCure Medical Ltd. announced a 1-for-30 reverse share split to regain compliance with the Nasdaq $1.00 minimum bid price requirement and support its broader capital markets strategy. The split, approved by shareholders and the board, will reduce the number of outstanding shares from approximately 84.2 million to 2.8 million. Trading on a split-adjusted basis is set to begin on June 4, 2026, as the company proactively addresses regulatory requirements to maintain its Nasdaq listing.
Key Highlights
- IceCure Medical will effect a 1-for-30 reverse share split.
- The primary purpose is to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
- Split-adjusted trading will begin on June 4, 2026, under the existing symbol "ICCM".
- Outstanding shares will decrease from 84,201,034 to approximately 2,806,701.
- No fractional shares will be issued; all fractional shares will be rounded to the nearest whole share.
- The reverse split was approved by shareholders on May 11, 2026, and the board approved the 1-for-30 ratio.
- Proportional adjustments will be made to outstanding options, warrants, and share incentive plans.
Price Impact
More from ICCM